Lineage Cell Therapeutics (LCTX) Cash from Operations (2010 - 2026)

Lineage Cell Therapeutics has reported Cash from Operations for 17 years, with the latest figure at 8078000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 65.33% year-over-year to 8078000.0; the trailing twelve-month figure through Mar 2026 stood at 22111000.0 (changed 0.38% YoY), and the FY2025 full-year result was 18919000.0, up 18.07% from the prior year.
• Cash from Operations for Q1 2026 stood at 8078000.0, down from 4878000.0 in the prior quarter.
• The five-year high for Cash from Operations was 21904000.0 in Q1 2022, with the low at 11242000.0 in Q1 2023.
• Historically, Cash from Operations has averaged 4564470.59 across 5 years, with a median of 5783000.0 in 2024.
• Annual changes were most pronounced in 2022 — Cash from Operations jumped 395.04% — and 2023, when it slumped 151.32%.
• Lineage Cell Therapeutics' Cash from Operations stood at 8303000.0 in 2022, then advanced by 27.51% to 6019000.0 in 2023, then decreased by 5.43% to 6346000.0 in 2024, then advanced by 23.13% to 4878000.0 in 2025, then tumbled by 65.6% to 8078000.0 in 2026.
• The last three Cash from Operations figures came in at 8078000.0 (Q1 2026), 4878000.0 (Q4 2025), and 3616000.0 (Q3 2025), per Business Quant data.